乳腺癌即刻乳房重建术后放疗的研究进展  

Advances in postmastectomy radiotherapy in breast cancer patients with immediate breast reconstruction

作　　者：王明久 王淑莲 Wang Mingjiu;Wang Shulian(Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科,北京100021

出　　处：《中华放射肿瘤学杂志》2024年第6期567-571,共5页Chinese Journal of Radiation Oncology

摘　　要：乳腺癌是全球发病率第一的女性恶性肿瘤,治疗模式为手术为主的综合治疗。全乳切除术后放疗能够提高淋巴结阳性高危乳腺癌患者的局部区域控制率和生存率。随着生存的改善,患者对于生活质量和美容效果的需求也日益增高,全乳切除术后乳房重建提升了患者的生存质量。乳腺癌全乳切除术后即刻乳房重建术的应用逐年增加,给放疗带来了很大的挑战。放疗增加了重建并发症风险,乳房重建方式和放疗异质性会影响重建效果。本文就即刻乳房重建术后放疗并发症的主要影响因素、放疗的靶区、剂量和技术进行综述,同时对术前放疗联合即刻乳房重建的研究进展进行综述。Breast cancer is a female malignant tumor with the highest incidence rate worldwide,and surgery-based comprehensive treatment is the main treatment mode.Radiotherapy after total mastectomy can improve the regional control rate and survival rate of high-risk patients with lymph node positive breast cancer.With the improvement of survival,patients have increasing demand for the quality of life and cosmetic effects.Breast reconstruction after total mastectomy improves the quality of life of patients.The utilization of immediate breast reconstruction following mastectomy in breast cancer has been steadily increasing,which poses significant challenges for adjuvant radiotherapy if indicated.Radiotherapy is known to increase the risk of complications in the reconstructed breast,and the type of reconstruction and heterogeneity of radiotherapy can impact the outcomes of the reconstructed breast.In this article,we briefly review the principal factors influencing the complication risk of reconstructed breast after radiotherapy,and the appropriate radiation target delineation,dose fractionation and techniques.Furthermore,we provide an overview of the research in preoperative radiotherapy in the setting of immediate breast reconstruction.

关 键 词：乳腺肿瘤 全乳切除术 乳房重建 放射疗法 

分 类 号：R737.9[医药卫生—肿瘤]